This site is intended only for UK patients who have been prescribed Fasenra (benralizumab) for Severe Eosinophilic Asthma, or their caregiver

The Patient Information Leaflet for Fasenra is available here

This site is intended only for UK patients who have been prescribed Fasenra (benralizumab) for Severe Eosinophilic Asthma, or their caregiver

The Patient Information Leaflet for Fasenra is available here

  • Home
  • Learn more about FASENRA®
  • Help with self-administration
  • Helpful resources
  • Home
  • Learn more about FASENRA®
  • Help with self-administration
  • Helpful resources

Fasenra® resources are designed with your needs in mind

Welcome to the Fasenra® Connect360 website. Here, you’ll find information and resources designed to support you throughout your treatment journey with Fasenra®.

Fasenra® resources are designed with your needs in mind

Welcome to the Fasenra® Connect360 website. Here, you’ll find information and resources designed to support you throughout your treatment journey with Fasenra®.

 

Ready to explore the
resources Fasenra® has to offer to support your journey?

Some of the materials available are:

 Disease and treatment information

 Self-administration instructions

 Treatment plan

 Patient information booklet available in 12 languages

Visit resources

STARTING YOUR JOURNEY!

Learn more about Fasenra®

Help with self-administration

Educational Materials

GB-68632 I September 2025

Fasenra® (benralizumab) Connect 360, an AstraZeneca UK developed and funded website

The content on this website is intended only for UK patients who have been prescribed Fasenra (benralizumab) for Severe Eosinophilic Asthma, or their caregiver

I am not a UK patient who has been prescribed Fasenra, or their caregiver
  • Legal notice and terms of use
  • |
  • Contact Us
  • |
  • Privacy Policy
  • |
  • Cookie Notice

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

By reporting side effects, you can help provide more information on the safety of this medicine.

This is a non-promotional website developed and funded by AstraZeneca.

 

This site is intended to complement, not replace the 'Instructions for Use' and 'Patient Information Leaflet' (found in your medicine pack). Refer to these materials for additional important information.

 

If you have any questions or concerns about your treatment, you should always talk to your healthcare team.

 

FASENRA® is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca All rights reserved. GB-70406 I September 2025